Sustained TTK/PLK1 Inhibition by BAL0891, a Novel Mitotic Checkpoint Inhibitor, Drives Progressive Anti‑Leukemic Activity across Diverse AML Models (ICBMT 2026) - Oct 8, 2026 - Abstract #PP02‑06; "In conclusion, BAL0891 exhibits potent, time‑dependent anti‑leukemic activity mediated by the disruption of mitotic checkpoint signaling, with maximal efficacy requiring prolonged drug exposure. Crucially, its robust in vivo efficacy in the THP‑1 model demonstrates that BAL0891 can effectively suppress leukemia progression even in the context of TP53 mutation and limited venetoclax sensitivity, highlighting its potential as a promising therapeutic strategy for high‑risk AML. Keywords: Acute Myeloid Leukemia, BAL0891, TTK/PLK1 Dual Inhibitor, Mitotic Checkpoint, Venetoclax"
Checkpoint inhibition • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • PLK1 • THY1 • TP53
|
|
Mi Ji Choi 1; Bo‑Reum Kim 1; Jiyoung Moon 1; Hyunsong Son 1; Heejun Jeon 1; Hyeonju Yu 1; Minkyung Kang 2; Seunghyun Ma 3; Daehun Kwag 1; Hee‑Je Kim 1; Byung‑Sik Cho 1
|